Tremfya (guselkumab) / J&J 
Welcome,         Profile    Billing    Logout  
 11 Diseases   38 Trials   38 Trials   2772 News 


«12...2627282930313233343536...3839»
  • ||||||||||  Stelara (ustekinumab) / J&J
    Journal:  Anti-interleukin-23 agents for the treatment of ulcerative colitis. (Pubmed Central) -  Dec 23, 2020   
    Trials of other anti-IL-23 agents in UC are under way and designed to explore head-to-head efficacy with existing biologics, as well as the prospect of combination biological therapy. Apart from data on longer term efficacy and safety, future trials should also explore strategies to inform the positioning of IL-23 antagonists in therapeutic algorithms.
  • ||||||||||  Review, Journal:  Systematic Review on Rapidity of Onset of Action for Interleukin-17 and Interleukin-23 Inhibitors for Psoriasis. (Pubmed Central) -  Dec 18, 2020   
    The shortest time to 25% and 50% of patients to achieved PASI90 were seen with brodalumab 210mg every two weeks (Q2W) (3.5 weeks and 6.2 weeks, respectively), followed by ixekizumab 160mg Q2W (4.1 and 7.4 weeks, respectively) and ixekizumab 160mg Q4W (4.6 and 8.1 weeks, respectively) dosages. In conclusion, clinical trials yielded shorter time to onset of action in studies assessing approved dosing ranges of IL-17 inhibitors compared with studies assessing IL-23 inhibitors.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
    Journal:  Japanese guidance for use of biologics for psoriasis (the 2019 version). (Pubmed Central) -  Dec 18, 2020   
    Since 2015, three IL-17 inhibitors of secukinumab and ixekizumab, anti-IL-17A antibodies, and brodalumab, an anti-IL-17 receptor antibody, and two anti-IL-23p19 antibodies of guselkumab and risankizumab, have also been launched...The following can be listed as points to be considered for the selection of biologics: drug effects (e.g. strength of effectiveness, time to onset of effectiveness, effectiveness against arthritis, primary failure, secondary failure), safety (e.g. infections, administration-related reactions and relationships with other comorbidities), convenience for patients (e.g. hospital visit intervals, self-injection, maintenance therapy at clinics, feasibility of drug discontinuation/re-administration) and payment (medical costs) borne by patients. This guidance has been prepared with the aim of allowing dermatologists experienced in the treatment of psoriasis to use biologics appropriately according to the circumstances of individual patients after consideration of the above-mentioned factors.
  • ||||||||||  [VIRTUAL] Comparison of safety outcomes for treatments of moderate to severe plaque psoriasis through a network metaanalysis () -  Dec 6, 2020 - Abstract #SIDEMAST2020SIDEMAST_30;    
    Treatments assessed included risankizumab 150mg, brodalumab 210mg, guselkumab 100mg, ixekizumab 160mg, infliximab 5mg/kg, etanercept 25mg twice a week/50mg weekly, ustekinumab weight-based dose, secukinumab 300mg, adalimumab 40mg, apremilast 30mg, and dimethyl fumarate (DMF) 720mg. Risankizumab demonstrated a more favorable safety profile than other therapies for patients with moderate to severe psoriasis in this NMA.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
    [VIRTUAL] Long-term safety of guselkumab in patients with moderate-to-severe plaque psoriasis: integrated data through Week 156 of the phase 3 VOYAGE 1 and VOYAGE 2 Trials () -  Dec 6, 2020 - Abstract #SIDEMAST2020SIDEMAST_11;    
    Safety data were pooled across VOYAGE 1&2 through Week 156 and analyzed for the guselkumab group (patients randomized to guselkumab and patients randomized to placebo who crossed over to guselkumab) and the ALL guselkumab group (patients randomized to guselkumab, patients randomized to placebo who crossed over to guselkumab, and patients randomized to adalimumab who crossed over to guselkumab). Integrated safety data from the Phase 3 VOYAGE 1&2 studies revealed no new safety concerns for guselkumab through up to 3 years of treatment for moderate-to-severe psoriasis.
  • ||||||||||  Tremfya (guselkumab) / J&J
    New P4 trial:  TIG: Guselkumab Immunogenetics (clinicaltrials.gov) -  Nov 26, 2020   
    P4,  N=25, Not yet recruiting, 
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie, Differin (adapalene) / Galderma, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
    [VIRTUAL] Therapeutic Update () -  Nov 26, 2020 - Abstract #FCPANP2020FCPANP_61;    
    Similar concepts have allowed combination of halobetasol .01% and tazarotene .045%, calcipotriene as a foam and halobetasol as a lotion...Goldenberg also highlighted new topicals including tapinarof and a topical PDE-4 inhibitor, roflumilast...Goldenberg then summarized updates on biologics for the management of psoriasis including: the improved hemoglobin A1c and weight control in diabetic patients with psoriasis on Otezla (PDE-4 inhibitor); long-term safety of tumor necrosis factor biologics adalimumab and certolizumab pegol as well as the ability for patients to self-administer certolizumab at home; the enduring efficacy of IL-17 blockers including congruent patient-reported data for ixekizumab, sustained long-term response data for secukinumab to 52 weeks and for brodalumab to 60 weeks; data demonstrating that although IL-17 blockers (specifically secukinumab) may work faster, guselkumab had a higher proportion of patients reach PASI 90/100 by week 48 and that rizankizumab outperformed adalimumab in moderate to severe plaque psoriasis management; and finally promising results for tyrosine kinase 2 inhibitors improving quality of life in psoriasis patients...Goldenberg closed with a brief discussion of advancements in management of viral dermatoses (single-use cantharidin for molluscum, buccal-adhesive acyclovir tablets), personal care moisturizers, and augmenting sun protection with polypodium leucotomos. Overall, regardless of which niche in dermatology you practice in, there are sure to be exciting therapeutic advancements coming your way.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Enrollment closed:  G-PLUS: A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (clinicaltrials.gov) -  Nov 25, 2020   
    P3b,  N=117, Active, not recruiting, 
    Overall, regardless of which niche in dermatology you practice in, there are sure to be exciting therapeutic advancements coming your way. Recruiting --> Active, not recruiting
  • ||||||||||  Retrospective data, Journal:  Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. (Pubmed Central) -  Nov 7, 2020   
    This study provides an assessment of the comparative efficacy among treatments for moderate to severe plaque psoriasis. The meta-analysis suggests that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were associated with the highest PASI response rates in both short-term and long-term therapy.